Evidence map›Paper›PMID 31778316›Full record

ArticleThe British journal of radiology2020

Modulation of nanoparticle uptake, intracellular distribution, and retention with docetaxel to enhance radiotherapy.

Aaron Henry Bannister, Kyle Bromma, Wonmo Sung, Mesa Monica, Leah Cicon, Perry Howard, Robert L Chow, Jan Schuemann, Devika Basnagge Chithrani

Open access · bronzeAbstract read
In one paragraph

Article in The British journal of radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 32 citations in OpenAlex.

  1. Application of nano-radiosensitizers in combination cancer therapy.Bioengineering & translational medicine · 2023
    Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Advances in Gold Nanoparticle-Based Combined Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2020
    Review
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Aaron Henry BannisterDepartment of Physics and Astronomy, University of Victoria, Victoria, BC, Canada.
Kyle BrommaDepartment of Physics and Astronomy, University of Victoria, Victoria, BC, Canada.
Wonmo SungDepartment of Radiation Oncology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Mesa MonicaDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Leah CiconDepartment of Physics and Astronomy, University of Victoria, Victoria, BC, Canada.
Perry HowardDepartment of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada.
Robert L ChowDepartment of Biology, University of Victoria, Victoria, BC, Canada.
Jan SchuemannDepartment of Radiation Oncology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Devika Basnagge ChithraniDepartment of Physics and Astronomy, University of Victoria, Victoria, BC, Canada.ORCID http://orcid.org/0000-0001-5251-1388
University of Victoria · CAHarvard University · USBC Cancer Agency · CA

Funding

TOPAS - nBio, a Monte Carlo tool for radiation biology researchR01CA187003 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI SCHUEMANN, JAN PATRICK OSCAR · 2015 to 2024
$4.8M
NCI NIH HHS R01 CA187003
6 · The paper itself

Abstract

objectiveOne of the major issues in current radiotherapy (RT) is the normal tissue toxicity. A smart combination of agents within the tumor would allow lowering the RT dose required while minimizing the damage to healthy tissue surrounding the tumor. We chose gold nanoparticles (GNPs) and docetaxel (DTX) as our choice of two radiosensitizing agents. They have a different mechanism of action which could lead to a synergistic effect. Our first goal was to assess the variation in GNP uptake, distribution, and retention in the presence of DTX. Our second goal was to assess the therapeutic results of the triple combination, RT/GNPs/DTX.

methodsWe used HeLa and MDA-MB-231 cells for our study. Cells were incubated with GNPs (0.2 nM) in the absence and presence of DTX (50 nM) for 24 h to determine uptake, distribution, and retention of NPs. For RT experiments, treated cells were given a 2 Gy dose of 6 MV photons using a linear accelerator.

resultsConcurrent treatment of DTX and GNPs resulted in over 85% retention of GNPs in tumor cells. DTX treatment also forced GNPs to be closer to the most important target, the nucleus, resulting in a decrease in cell survival and increase in DNA damage with the triple combination of RT/ GNPs/DTX

conclusionThe ability to not only trap GNPs at clinically feasible doses but also to retain them within the cells could lead to meaningful fractionated treatments in future combined cancer therapy. Furthermore, the suggested triple combination of RT/GNPs/DTX may allow lowering the RT dose to spare surrounding healthy tissue. ADVANCES IN KNOWLEDGE: This is the first study to show intracellular GNP transport disruption by DTX, and its advantage in radiosensitization.

Indexed as

Metal NanoparticlesAntineoplastic AgentsBiological TransportCell SurvivalDocetaxelDrug SynergismFemaleGoldHeLa CellsHumansRadiation-Sensitizing AgentsTriple Negative Breast NeoplasmsTumor Cells, CulturedUterine Cervical NeoplasmsAntineoplastic AgentsDocetaxelGoldRadiation-Sensitizing Agents

Identifiers

PMID31778316
PMCPMC7055427
OpenAlexW2990784324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.